Condition: Mitral Valve Disease · Sponsor: French Cardiology Society
The objective of this study is to collect in a prospective registry all cases of French patients undergoing an assessment for percutaneous treatment of mitral valve disease on a native valve or due to deterioration after surgical valve repair or replacement. In these patients, valvular surgery should be considered contra-indicated or at prohibitive risk. This registry will evaluate the morbidity and mortality up to 24 months for those patients with severe mitral valve disease who are not included in a clinical trial. The association of demographic, clinical, laboratory, echocardiographic variables and treatment options with morbidity and mortality will be evaluated by univariate and multivariate analyses.
This description comes directly from the study's public registry record.
Jean-François OBADIA · +331 43 22 33 33 · secretariat.registre@sfcardio.fr
Bernard IUNG · +331 43 22 33 33 · secretariat.registre@sfcardio.fr
Always discuss trial participation with your own doctor first.
| CHU Lyon | Lyon, France | Recruiting |
| CHU Nantes | Nantes, France | Recruiting |
| Bichat Hospital | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02925819